Tag Archives: mitral failure

TCT 2022

TCT 2022 | CLASP II D TRIAL: Transcatheter Edge-to-Edge Repair for Mitral Regurgitation in Patients at Prohibitive Risk

TCT 2022 | CLASP II D TRIAL: Transcatheter Edge-to-Edge Repair for Mitral Regurgitation in Patients at Prohibitive Risk

The CLASP IID study was a prospective randomized study to assess the efficacy and effectiveness of the PASCAL transcatheter valve repair system compared with the MitraClip device for patients with degenerative mitral regurgitation (MR) at prohibitive surgical risk. The study included Patients at prohibitive surgical risk, candidates for both devices, with MR 3+ to 4+,

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Is the Cause of Mitral Regurgitation Relevant for MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old. This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR).   FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

MitraClip in Patients with COPD: a Valid Option

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are associated to hospitalization and mortality.  When associated to severe mitral regurgitation, not only do these two conditions have poor evolution, but they also limit the possibility of surgical valve replacement, given its high risk. Edge-to-edge repair with MitraClip has been shown beneficial in a group of

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

MitraClip Reduces Renal Function Deterioration

Severe mitral regurgitation is associated to cardiac failure and hospitalization and over time is accompanied by kidney failure, which leads to higher mortality.  In the COAPT study, in patients with low ejection fraction, MitraClip showed benefits over medical treatment, but there was an important group of people with kidney function deterioration.  The evolution and benefit

EuroPCR 2022

EuroPCR 2022 | The MITRA TUNE Registry

Left atrial enlargement with or without atrial fibrillation (AF), absence of valvular degeneration, and heart failure with preserved function have recently been identified as functional atrial mitral regurgitation (MR). This subtype of secondary MR currently appears to be underdiagnosed, and the need for treatment in the general population might be greater than predicted. The aim

Is High Mean Gradient After Edge-to-Edge Strategy Important?

Edge-to-edge treatment of the mitral valve is currently a valid alternative to surgery in cases of mitral regurgitation. Different studies have taken residual mitral regurgitation as a parameter of success, but little research has been conducted on the residual gradient once the procedure has been completed.  What has been published is that a mean gradient

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version.  In this regard, below you will find what has been called “10 commandments” that sum up this new document, to keep you in the loop.  The incidence

EuroPCR 2020 | EVOQUE: nuevo sistema de reemplazo mitral por catéter, promesas a corto plazo y esperanzas para el futuro

EuroPCR 2020 | CLASP: New Device for Mitral Repair with at One Year Follow Up

The CLASP looked into patients treated with the new device for transcatheter mitral repair called PASCAL and showed low complications rate, high survival rate, significant mitral regurgitation reduction and improved quality of life at one year.  In July 2019 we published on our web page the 30 year outcomes of the PASCAL device () which

Estenosis aórtica moderada y disfunción ventricular ¿debería apurarse la indicación del recambio?

Treating Both Atrial Valves Improves Survival

Courtesy of Dr. Carlos Fava. There a few treatment options for tricuspid valve disease. It is practically limited to diuretics and surgery, is associated to high mortality and, generally, mitral regurgitation.  Developing the “edge-to-edge” strategy with MitraClip has been shown beneficial and, at present, there are studies that claim this technique could be greatly beneficial

MitraClip frecuencia ritmo cardíaco

Can We Treat Severe Residual Mitral Regurgitation after MitraClip without Surgery?

Courtesy of Dr. Carlos Fava. Edge to edge with MitraClip was shown effective and safe, and its outcomes have been improving over these past few years. However, one of its greatest challenges involves not being able to reduce mitral regurgitation (MR) after device implantation, resulting in the need for surgery, as some studies have shown